Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene resulting in a deficiency of factor VIII protein. Lentigen and Expression Therapeutics will develop two types of treatments for Hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder.
“Hemophilia A is a serious disease, affecting about one in 10,000 people worldwide,” explained Dr.
“The platform technology developed by Expression Therapeutics will be used to advance the treatment of hemophilia A. By combining our high expression factor VIII technology with Lentigen’s protein expression and gene transfer capabilities, we are confident Lentigen is the ideal partner to help bring this technology to the clinic and marketplace,” stated Dr.
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, The
About Expression Therapeutics
Expression Therapeutics, LLC is a privately owned biotechnology company in
Lentigen Media Contacts: Richard Lewis Communications, Inc. (212) 827-0020 Gregory Tiberend, firstname.lastname@example.org Cecelia Heer, email@example.com Expression Therapeutics Media Contacts: Gabriela Denning, firstname.lastname@example.org (678) 278-1140 Keith Kerstann, email@example.com
SOURCE Lentigen Corporation